News and Updates
iVeena announces the appointment of Robert Dempsey, Group Vice President and Head of the Global Ophthalmology Franchise at Takeda (formerly Shire) to the iVeena Board of Directors
iVeena announces the appointment of Robert Dempsey, Group Vice President and Head of the Global Ophthalmology Franchise at Takeda (formerly Shire) to the iVeena Board of Directors. “Mr. Dempsey will
iVeena announces the addition of internationally known Key Opinion Leader and entrepreneur, Dr. Richard Lindstrom, MD to the iVeena Scientific Advisory Board.
Read about Dr. Lindstrom
iVeena awarded top prize for most promising new products in the field of ophthalmology at the American Society of Cataract and Refractive Surgeons annual conference.
iVeena receives top award at the American Society of Cataract and Refractive Surgeons At the May 4, 2019 American Society of Cataract and Refractive Surgeons, Dr. Ambati (iVeena President and Founde
iVeena announces the commencement of a 36 patient Phase 1/2a pilot clinical study for the treatment of keratoconus.
iVeena announces the commencement of a 36 patient Phase I/2a pilot clinical study for the treatment of Keratoconus (IVMED-80). The Company has Orphan Drug Designation for this product. Keratoconus
Mountain Pacific Venture Fund invests in ocular drug development company iVeena
iVeena announces the first close for its $2.75M Series B financing by Mountain Pacific Venture Fund, a health care/biotech focused venture fund. Press release attached or continue below: Contact
Page 4 of 9